Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 33 citing articles:

Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, et al.
Liver Cancer (2023) Vol. 12, Iss. 4, pp. 321-338
Open Access | Times Cited: 67
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, et al.
Liver Cancer (2023) Vol. 13, Iss. 1, pp. 99-112
Open Access | Times Cited: 42
Cisplatin in Liver Cancer Therapy
Sae Hamaya, Kyoko Oura, Asahiro Morishita, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10858-10858
Open Access | Times Cited: 41
Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma
Katsuki Miyazaki, Yuji Morine, Caiming Xu, et al.
Cells (2023) Vol. 12, Iss. 4, pp. 612-612
Open Access | Times Cited: 19
A multitask deep learning radiomics model for predicting the macrotrabecular-massive subtype and prognosis of hepatocellular carcinoma after hepatic arterial infusion chemotherapy
Xuelei He, Kai Li, Ran Wei, et al.
La radiologia medica (2023) Vol. 128, Iss. 12, pp. 1508-1520
Open Access | Times Cited: 16
Postprogression treatment of lenvatinib plus PD‐1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy
Chao An, Yan Fu, Wang Li, et al.
Cancer (2023) Vol. 129, Iss. 14, pp. 2235-2244
Closed Access | Times Cited: 14
Local-region treatment comparison following conversion therapy of hepatocellular carcinoma: a period and age-dependent analysis
Jiahui Hu, Shu Zhao, Mengxuan Zuo, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Surgical resection versus thermal ablation: comparison of sequential options after successful TACE downstaging therapy for unresectable hepatocellular carcinoma
Chao An, Songsong Wu, Mengxuan Zuo, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
A Prospective, Single-Arm, Phase 2 Study of Modified Transarterial Chemoembolization Using Low-Dose Chemotherapy with Blank Microspheres Plus Low-Dose Lenvatinib and Microwave Ablation in Patients with Large (≥7 cm) Unresectable Hepatocellular Carcinoma: The TALEM Trial
Zhimei Huang, Xue Han, Jian Wang, et al.
Liver Cancer (2024) Vol. 13, Iss. 4, pp. 438-450
Open Access | Times Cited: 3
Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis
YiFeng Liang, L M Gan, DeJin Zeng, et al.
Clinical & Translational Oncology (2024) Vol. 26, Iss. 10, pp. 2652-2664
Closed Access | Times Cited: 3
Predictive Factors of Complete Response to Transarterial Chemoembolization in Intermediate Stage Hepatocellular Carcinoma beyond Up-To-7 Criteria
Natsuhiko Saito, Hideyuki Nishiofuku, Takeshi Sato, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2609-2609
Open Access | Times Cited: 8
Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma
Yusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 3789-3789
Open Access | Times Cited: 8
Vascular Normalization Caused by Short-Term Lenvatinib Could Enhance Transarterial Chemoembolization in Hepatocellular Carcinoma
Tetsuya Tachiiri, Hideyuki Nishiofuku, Shinsaku Maeda, et al.
Current Oncology (2023) Vol. 30, Iss. 5, pp. 4779-4786
Open Access | Times Cited: 7
Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis
Dailong Li, Siqi Liu, Chunlai Cheng, et al.
Medicine (2023) Vol. 102, Iss. 35, pp. e34811-e34811
Open Access | Times Cited: 7
Child–Pugh grade deterioration stratified by the etiology after transcatheter arterial chemoembolization as initial treatment for hepatocellular carcinoma
Kengo Yoshitomi, Tsuguru Hayashi, Shinji Oe, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Multimodal imaging-based prediction of recurrence for unresectable HCC after downstage and resection-cohort study
Hanyu Jiang, Mengxuan Zuo, Wang Li, et al.
International Journal of Surgery (2024) Vol. 110, Iss. 9, pp. 5672-5684
Open Access | Times Cited: 2
Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan
Masatoshi Kudo
Liver Cancer (2023) Vol. 12, Iss. 6, pp. 497-509
Open Access | Times Cited: 6
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects
Masatoshi Kudo
Liver Cancer (2022) Vol. 11, Iss. 6, pp. 487-496
Open Access | Times Cited: 9
Safety and Efficacy of TACE + Lenvatinib in Treating Advanced Hepatocellular Carcinoma: A Systematic Review and Meta- analysis
Di Pan, Haonan Liu, Xiao Ma, et al.
Journal of Gastrointestinal and Liver Diseases (2023) Vol. 32, Iss. 2, pp. 222-229
Open Access | Times Cited: 4
Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts
Michihisa Moriguchi, Seita Kataoka, Yoshito Itoh
Cancers (2024) Vol. 16, Iss. 13, pp. 2387-2387
Open Access | Times Cited: 1
An Evaluation of the Most Convenient and Effective Procedure for Reducing the Loading Time of Epirubicin Into the Drug-Eluting Bead M1 (DC Bead M1™)
Yusuke Kawamura, Norio Akuta, Shigeki Yamamoto, et al.
Cureus (2024)
Open Access | Times Cited: 1
Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma
Yusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Clinical Journal of Gastroenterology (2022) Vol. 16, Iss. 1, pp. 1-12
Closed Access | Times Cited: 6
Two Cases of Advanced Hepatocellular Carcinoma Who Responded Well to the Combination of Durvalumab Plus Tremelimumab After Disease Progression During Atezolizumab Plus Bevacizumab Therapy Under Bevacizumab Withdrawal
Yusuke Kawamura, Norio Akuta, Shunichiro Fujiyama, et al.
Cureus (2023)
Open Access | Times Cited: 3
Efficacy and safety of lenvatinib–transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study
Ko Oshita, Tsuyoshi Kobayashi, Yosuke Namba, et al.
BMJ Open (2023) Vol. 13, Iss. 10, pp. e073797-e073797
Open Access | Times Cited: 2
Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma
Seiichi Mawatari, Tsutomu Tamai, Kotaro Kumagai, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6139-6139
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top